Clinical trials: Allergic Disease
Contact Dermatitis
Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis
This two cohort study (Cohort A and B) is being conducted to assess the safety and efficacy of BBI-2000 for the prevention (Cohort A) and treatment (Cohort B) of delayed type hypersensitivity reaction.
- Trial name
- BBI (NCT03089775)
- Testing
- BBI-2000, Vehicle, Multiple treatments
- Where
- Canada
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Fresh Tracks Therapeutics, Inc.
Asthma
Study Evaluating the Effects of AIR645 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma
To assess the efficacy of inhaled AIR645 in the suppression of the Asthmatic Responses in subjects with mild asthma inhaling an allergen.
- Trial name
- NCT00941577
- Testing
- AIR645, Physiologic saline solution
- Where
- 3 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Altair Therapeutics, Inc.
Allergic Rhinitis
Nasya in Allergic Rhinitis
The purpose of this study is to evaluate safety and efficacy of Nasya in reducing symptoms of persistent allergic rhinitis when applied before allergen challenge.
- Trial name
- NCT01503957
- Testing
- Nasya, Saline solution
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- InQpharm Group
Rhinitis, Allergic, Seasonal
Study In Adults And Adolescents With Seasonal Allergic Rhinitis.
Compare the efficacy and safety of an investigational nasal spray compared with placebo nasal spray in the treatment of seasonal allergic rhinitis.
- Trial name
- NCT00225823
- Testing
- GW685698X
- Where
- 24 sites in Estonia, Latvia and 4 more
- Volunteers
- 288 people
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis
Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848
The primary purpose is to investigate tolerability/safety of repeated weekly doses of AZD8848 administered intranasally to seasonal allergic rhinitis patients.
- Trial name
- NCT00770003
- Testing
- AZD8848
- Where
- 2 sites in Sweden
- Volunteers
- 103 people
- Sponsor
- AstraZeneca
Conjunctivitis, Allergic
Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Relestat Ophthalmic Solution 0.05% in patients with allergic conjunctivitis who are treated with Relestat as standard of care in…
- Trial name
- NCT01987765
- Testing
- Relestat Ophthalmic Solution 0.05%
- Where
- South Korea
- Volunteers
- 847 people
- Sponsor
- Allergan
Allergic Rhinitis
Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol
The purpose of this study is to compare the systemic levels of beclomethasone 17 monopropionate (17 BMP - the active metabolite of BDP) after intranasal administration of BDP HFA with the systemic levels of 17 BMP after…
- Trial name
- NCT01537692
- Testing
- BDP HFA Nasal Aerosol, BDP HFA Inhalation Aerosol (QVAR)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Allergic Asthma
A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers
This is a phase I an open-label randomized comparative study in parallel groups of pharmacokinetics, pharmacodynamics, immunogenicity, and safety of Genolair in two dosage forms (solution for subcutaneous administration and…
- Trial name
- NCT06494345
- Testing
- Genolair, solution for subcutaneous administration, 150 mg, Genolair, lyophilisate for the preparation of solution for subcutaneous administration, Xolair®, solution for subcutaneous administration, 150 mg
- Where
- Russia
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- AO GENERIUM
Allergy
Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants
The purposes of this study are to assess the efficacy, safety and tolerability of a single dose of REGN1908-1909 in allergic adult participants, to collect information about how much REGN1908-1909 is in blood over time and to…
- Trial name
- NCT02127801
- Testing
- REGN1908-1909
- Where
- 5 sites in Netherlands, New Zealand and 2 more
- Volunteers
- 74 people
- Sponsor
- Regeneron Pharmaceuticals
House Dust Mite Allergy, House Dust Mite Rhinitis
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
Rationale: Allergic rhinitis/rhinoconjunctivitis (ARC) is a global health problem, affecting 10-25% of the population. Allergen-specific immunotherapy is the only disease-modifying therapeutic option for subjects with house dust…
- Trial name
- NCT06920771
- Testing
- PURETHAL Mites 50,000 AUeq/ml
- Where
- 68 sites in Bulgaria, Germany and 3 more
- Volunteers
- 691 people
- Sponsor
- HAL Allergy
Allergic Rhinitis, Allergic Conjunctivitis
Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray
Intranasal corticosteroids are accepted as safe and effective first-line therapy for allergic rhinitis, especially in treatment of persistent symptoms.
- Conditions
- Allergic Rhinitis, Allergic Conjunctivitis, Hayfever
- Trial name
- NCT03755557
- Testing
- Rhinocort, Budesolv
- Where
- Austria
- Volunteers
- 82 people
- Sponsor
- Marinomed Biotech AG
Rhinitis, Rhinoconjunctivitis
Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma
This is an open-label, non-controlled, non-randomised, prospective safety study in patients with rhinitis or allergic rhinoconjunctivitis, with controlled asthma, and clinically relevant sensitisation to dust mites from the…
- Conditions
- Rhinitis, Rhinoconjunctivitis, Asthma
- Trial name
- NCT02340130
- Testing
- DP/MG/14-1, DP/MG/14-2
- Where
- 3 sites in Spain
- Volunteers
- 57 people
- Sponsor
- Laboratorios Leti, S.L.
Post-nasal Drip, Seasonal Allergic Rhinitis
Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)
This was a 1-week study of desloratadine (DL) plus oxybutynin (OXY) at two dose levels in the treatment of post-nasal drip in participants with seasonal allergic rhinitis.
- Conditions
- Post-nasal Drip, Seasonal Allergic Rhinitis, Rhinorrhea
- Trial name
- NCT00816972
- Testing
- Desloratadine 2.5 mg, Oxybutynin 2.5 mg
- Volunteers
- 540 people
- Sponsor
- Organon and Co
Allergic Rhinitis
The Effect of Allergic Rhinitis on Educational Outcomes
The study will assess the the burden of living with allergic rhinitis (AR) and the effect of AR on school performance for children and adolescents in Denmark.
- Trial name
- NCT05881577
- Testing
- Observational
- Where
- Denmark
- Volunteers
- 150,000 people
- Sponsor
- ALK-Abelló A/S
Rhinitis, Allergic, Seasonal, Seasonal Allergic Rhinitis
Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber
This study is in patients with seasonal allergic rhinitis(SAR)and will compare the effect versus placebo of repeat doses of intranasal GSK256066 using the Vienna Challenge Chamber.
- Trial name
- NCT00377728
- Testing
- GSK256066
- Where
- Austria
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Allergic Conjunctivitis
A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis
- Trial name
- NCT03231969
- Testing
- Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6%
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Faes Farma, S.A.
Seasonal Allergic Rhinitis
Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial
Comparison of two nasal sprays for the treatment of seasonal allergic rhinitis
- Trial name
- NCT00691665
- Testing
- Olopatadine HCL Nasal Spray, 0.6%, Fluticasone Propionate Nasal Spray, 50 mcg
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Seasonal Allergic Rhinitis
Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray, 140 mcg + 50 mcg, (Glenmark, India) Administered as a Monotherapy to Patients With Seasonal Allergic Rhinitis.
Prospective, multicenter, open, randomized, parallel, clinical study for assessment of comparative efficacy and safety of Azelastine +Mometasone Sandoz (main group) and Momat Rino Advance (control group) administered as a…
- Trial name
- NCT05590598
- Testing
- Azelastine + Mometazone, nasal spray, Momat Rhino Advance
- Where
- 15 sites in Russia
- Volunteers
- 472 people
- Sponsor
- Sandoz
Allergic Rhinitis
Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis
The objectives of this study were to: Examine the tolerability of two formulations and two dose concentrations of epinastine. Select formulation(s) of epinastine for future studies by evaluating the individual sensory attribute…
- Trial name
- NCT01382654
- Testing
- epinastine 0.1%, epinastine 0.1% with taste masking agent, epinastine 0.2%
- Volunteers
- 131 people
- Sponsor
- Merck Sharp & Dohme LLC
Peanut Allergy
Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children
This is an open label expanded access program for male and female patients 2 years or older, to provide continued desensitization treatment with DBV712 250 mcg.
- Trial name
- NCT05424731
- Testing
- DBV712 250 mcg
- Where
- United States
- Sponsor
- DBV Technologies
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.